Durect
Durect
DRRX
NASDAQ
0.80
USD
0.00%
About
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored.
Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 60.4K |
| Three Month Average Volume | 1.9M |
| High Low | |
| Fifty-Two Week High | 3.14 USD |
| Fifty-Two Week Low | 0.4703 USD |
| Fifty-Two Week High Date | 02 Nov 2023 |
| Fifty-Two Week Low Date | 10 Nov 2023 |
| Price and Volume | |
| Current Price | 1.48 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -7.83% |
| Thirteen Week Relative Price Change | -19.13% |
| Twenty-Six Week Relative Price Change | 37.17% |
| Fifty-Two Week Relative Price Change | -61.40% |
| Year-to-Date Relative Price Change | 111.83% |
| Price Change | |
| One Day Price Change | 3.50% |
| Thirteen Week Price Change | -13.45% |
| Twenty-Six Week Price Change | 50.82% |
| Five Day Price Change | 3.50% |
| Fifty-Two Week Price Change | -51.63% |
| Year-to-Date Price Change | 150.85% |
| Month-to-Date Price Change | -9.20% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.48734 USD |
| Book Value Per Share (Most Recent Quarter) | 0.16228 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.28397 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.03647 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.84234 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.32556 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.28419 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.0521 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.52833 USD |
| Normalized (Last Fiscal Year) | -1.0521 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.0521 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.52833 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.0521 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.52833 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.97844 USD |
| Cash Per Share (Most Recent Quarter) | 0.50408 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.04647 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.53375 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.88704 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -130 |
| Cash Flow Revenue (Trailing Twelve Months) | -312 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -187.84% |
| Pretax Margin (Last Fiscal Year) | -323.16% |
| Pretax Margin (5 Year) | -139.11% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 79.91% |
| Gross Margin (Trailing Twelve Months) | 80.80% |
| Gross Margin (5 Year) | 91.83% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -431.49% |
| Operating Margin (Trailing Twelve Months) | -296.42% |
| Operating Margin (5 Year) | -143.10% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -323.16% |
| Net Profit Margin (Trailing Twelve Months) | -187.84% |
| Net Profit Margin (5 Year) | -139.11% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -16.96% |
| Tangible Book Value (5 Year) | -8.73% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 4.32% |
| Revenue Growth (3 Year) | -10.96% |
| Revenue Change (Trailing Twelve Months) | -56.70% |
| Revenue Per Share Growth | -19.38% |
| Revenue Growth (5 Year) | -34.28% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -10.98% |
| Total Debt (5 Year) | -4.09% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 73.87% |
| EPS Change (Trailing Twelve Months) | 65.43% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -3,101,000 |
| Net Debt (Last Fiscal Year) | -13,017,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 9 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -34,466,000 |
| Free Cash Flow (Trailing Twelve Months) | -26,253,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -56 |
| Net Interest Coverage (Trailing Twelve Months) | -39 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 113 |
| Total Debt to Equity (Most Recent Quarter) | 249 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -52.47% |
| Return on Assets (Trailing Twelve Months) | -40.25% |
| Return on Assets (5 Year) | -37.34% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -138.93% |
| Return on Equity (Trailing Twelve Months) | -299.88% |
| Return on Equity (5 Year) | -82.71% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -124.79% |
| Return on Investment (Trailing Twelve Months) | -208.53% |
| Return on Investment (5 Year) | -53.44% |